Endothelial dysfunction providing the basis for the treatment of pulmonary hypertension: Giles F. Filley lecture

Chest

Volumn 114, Issue 1 SUPPL., 1998, Pages

  Higenbottam, Timothy W ^a   Laude, Elizabeth A ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; ACETYLCHOLINE; ADENOSINE DIPHOSPHATE; ARGININE; CALCIMYCIN; ENDOTHELIN 1; ENDOTHELIN RECEPTOR; ENDOTHELIUM DERIVED RELAXING FACTOR; ILOPROST; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE; NITROPRUSSIDE SODIUM; PROSTACYCLIN; SEROTONIN; THROMBOXANE A2; THROMBOXANE B2; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR GATA 1;

BLOOD VESSEL REACTIVITY; CLINICAL TRIAL; CONFERENCE PAPER; ENDOTHELIUM LESION; GENE EXPRESSION; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG BLOOD FLOW; LUNG ENDOTHELIUM; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSTAGLANDIN METABOLISM; PULMONARY ARTERY; PULMONARY HYPERTENSION; SEROTONIN BLOOD LEVEL; SIGNAL TRANSDUCTION; THROMBOCYTE RELEASE REACTION; VASCULAR SMOOTH MUSCLE;

EID: 0031854540     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (77)

1. de Hoyos AL, Patterson GA, Maurer JR, et al. Pulmonary transplantation: early and late results: the Toronto Lung Transplant Group. J Thorac Cardiovasc Surg 1992; 103:295-306
2. Penketh A, Higenbottam T, Hakim M, et al. Heart and lung transplantation in patients with end stage lung disease. BMJ 1987; 295:311-14
3. Fuster V, Steele PM, Edwards WD, et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984; 70:580-87
4. Hosenpud JD, Novick RJ, Bennett LE, et al. The registry of the International Society for Heart and Lung Transplantation: 13th official report - 1996. J Heart Lung Transplant 1996; 15:655-74
5. Hakim M, Higenbottam TW, Bethune D, et al. Selection and procurement of combined heart and lung grafts for transplantation. J Thorac Cardiovasc Surg 1988; 95:474-79
6. Sharples LD, Tamm M, McNeil K, et al. Development of bronchiolitis obliterans syndrome in recipients of heart lung transplantation - early risk factors. Transplantation 1996; 61: 560-66
7. Nocturnal Oxygen Therapy Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease. Ann Intern Med 1980; 93:391-98
8. Stuart-Harris C, Bishop JM, Clark TJH, et al. Long-term domiciliary oxygen therapy in chronic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981; 1:681-85
9. Abraham AS, Cole RB, Bishop JM. Reversal of pulmonary hypertension by prolonged oxygen administration to patients with chronic bronchitis. Circ Res 1968; 23:147-57
10. Weitzenblum E, Sautegeau A, Ehrhart M, et al. Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1985; 131:493-98
11. Vane JR, Anggard EE, Botting RM. Regulatory functions of the vascular endothelium. N Engl J Med 1990; 323:27-36
12. Higenbottam TW. Prostacyclin. Bandolier. 1995; 14:3-4
13. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide, physiology, pathophysiology and pharmacology. Pharmacol Rev 1991; 43:109-42
14. Michael JR, Markewitz BA. Endothelins and the lung. Am J Respir Crit Care Med 1996; 154:555-75
15. Moncada S, Gryglewski RJ, Bunting S, et al. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregatiou. Nature 1976; 263:663-65
16. Ritter JM, Blair IA, Barrow SE, et al. Release of prostacylin in vivo and its role in man. Lancet 1983; 1:317-19
17. 2. J Appl Physiol 1978; 45:408-13
18. Gryglewski RJ, Szczeklik A, Nizankowski R. Anti-platelet action of intravenous infusion of prostacyclin in man. Thromb Res 1978; 13:153-63
19. Zusman RM, Rubin RH, Cato AE, et al. Hemodialysis using prostacyclin instead of heparin as the sole antithrombotic agent. N Engl J Med 1981; 304:934-39
20. Weir EK, Rubin LJ, Ayers SM, et al. The acute administration of vasodilators in pulmonary hypertension - experience from the National Institutes of Health Registry on primary pulmonary hypertension. Am Rev Respir Dis 1989; 140: 1623-30
21. Higenbottam TW, Spiegelhalter D, Scott JP, et al. Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension. Br Heart J 1993; 70:366-70
22. Higenbottam TW, Wheeldon D, Wells F, et al. Long term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet 1984; 1:1046-47
23. Barst RJ, Rubin LR, Mcgoon MD, et al. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994; 121:409-15
24. De La Mata J, Gomez-Sanchez MA, Aranzana M, et al. Long-term iloprost infusion therapy for severe pulmonary hypertension in patients with connective tissue diseases. Arthritis Rheum 1994; 37:1528-33
25. Saji T, Ozawa Y, Natayama T, et al. Short- and long-term effects of the new oral prostacyclin analogue, beraprost sodium in patients with severe pulmonary hypertension. J Cardiol 1996; 27:197-205
26. Olschewski H, Walmrath D, Schermuly R, et al. Aerosolised prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 1996; 124:820-24
27. Crofford LJ. COX 1 and COX 2 tissue expression: implications and predictions. J Pharmacol 1997; 24(suppl 49):15-19
28. Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 1975; 72:2994-98
29. Ronni-Siviula H, Malm H, Ylikorkala O, et al. Marathon runs stimulate more prostacyclin than thromboxane synthesis and differ in men and women. Prostaglandins 1993; 46:75-79
30. 2 metabolites during leg exercise in humans. Am J Physiol 1988; 255:1115-18
31. Watkins MT, Haudenschild CC, al Badawi H, et al. Immediate responses of endothelial cells to hypoxia and reoxygenation: an in vitro model ol cellular dysfunction. Am J Physiol 1995; 268:H749-58
32. Shaul PW, Kinane B, Farrar MA, et al. Prostacyclin production and mediation of adenylate cyclase activity in the pulmonary artery alters after prolonged hypoxia in the rat. J Clin Invest 1991; 88:447-55
33. Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 327:70-75
34. Higenbottam TW, Spiegelhalter D, Scott JP, et al. Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension. Br Heart J 1993; 70:360-70
35. Furchgott RF. Role of the endothelium in responses of vascular smooth muscle. Circ Res 1983; 53:557-73
36. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelial derived relaxing factor. Nature 1987; 327:524-26
37. Palmer RMJ, Moncada S. A novel eitrulline-forming enzyme implicated in the formation of nitric oxide by vascular endothelial cells. Biochem Biophys Res Commun 1989; 158: 348-52
38. Palmer RMJ, Ashton DS, Moncada S. Vascular endothelial cells synthesise nitric oxide from L-arginine. Nature 1988; 333:604-60
39. Forstermann U, Kleinert H. Nitric oxide synthase: expression and expressional control of the three isoforms. Naunyn Schmeidebergs Arch Pharmacol 1995; 352:351-64
40. Murrell W. Nitro-glycerine as a remedy for angina pectoris. Lancet 1879; 1:80-81
41. Borland CDR, Higenbottam TW. A simultaneous single breath measurement of pulmonary diffusing capacity with nitric oxide and carbon monoxide. Eur Respir J 1989; 2:56-63
42. Ignarro LJ. Haem-dependent activation of guanylate cyclase and cyclic GMP formation by endogenous nitric oxide: a unique transduction mechanism for transcellular signaling. Pharmacol Toxicol 1990; 67:1-7
43. Gruetter CA, Barry BK, McNamara DB, et al. Relaxation of bovine coronary artery and activation of coronary arterial guanylate cyclase by nitric oxide, nitroprusside and a carcinogenic nitrosoamine. J Cyclic Nucleotide Res 1979; 5:211-24
44. Higenbottam T, Pepke-Zaba J, Scott J, et al. Inhaled endothelian-derived relaxing factor (EDRF) in primary pulmonary hypertension (PPH). Am Rev Respir Dis 1988; 137:A107
45. Rossiant R, Falke KJ, Lopez F, et al. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med 1993; 328:399-405
46. Kinsella JP, Neish SR, Shaffer E, et al. Low dose inhalational nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 1992; 340:819-20
47. Roberts JD, Poloaner DM, Lang P, et al. Inhaled nitric oxide iu persistent pulmonary hypertension of the newborn. Lancet 1992; 340:818-19
48. Channick RN, Newhart JW, Johnson FW, et al. Pulsed delivery of inhaled nitric oxide to patients with pulmonary hypertension. Chest 1996; 109:1545-49
49. Vesal N, Cremona G, Katayama Y, et al. Optimal inhalation of nitric oxide using the spiked method [abstract]. Am J Respir Crit Care Med 1995; 151:A729
50. Rees DD, Palmer RJM, Schulz R, et al. Characterisation of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol 1990; 101:746-52
51. Dinh-Xuan AT, Higenbottam TW, Clelland CA, et al. Impairment of endothelium-dependent pulmonary artery relaxation of chronic obstructive lung disease. N Engl J Med 1991; 324:1539-47
52. Dinh Xann AT, Pepke-Zaba J, Butt AY, et al. Impairment of pulmonary artery endothelium-dependent relaxation in chronic obstructive lung disease is not due to dysfunction of endothelial cell membrane receptors nor to L-arginine deficiency. Br J Pharmacol 1993; 109:587-91
53. Cremona G, Wood AM, Hall LW, et al. The effects of inhibitors of nitric oxide release and action on vascular resistance in isolated lungs of pig, sheep, dog and man. J Physiol 1994; 48:185-95
54. Cremona G, Higenbottam T, Takao M, et al. Exhaled nitric oxide in isolated pig lungs. J Appl Physiol 1995; 78:59-63
55. Hakim TS. Flow induced release of EDRF in the pulmonary vasculature: site of release and action. Am J Physiol 1994; 267(Heart Circ Physiol 36): H363-69
56. Cremona G, Higenbottam T, Borland C, et al. Mixed expired air in primary pulmonary hypertension in relation to lung diffusion capacity. Q J Med 1994; 87:547-51
57. Borland C, Cox Y, Higenbottam TW. Measurement of exhaled nitric oxide in man. Thorax 1993; 48:1160-62
58. Pietra GG, Edwards WD, Kay JM, et al. Histopathology of primary pulmonary hypertension: a qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation 1989; 80:1198-1206
59. Borland C, Cox Y, Higenbottam T. Reduction of pulmonary capillary blood volume is reduced in patients with severe unexplained pulmonary hypertension. Thorax 1996; 51:855-56
60. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995; 333:214-21
61. Xue C, Johns RA. Endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension [letter], N Engl J Med 1995; 333:1642-44
62. Springall DR, Mason NA, Burke M, et al. Endothelial (type-iii) nitric-oxide synthase is highly expressed in plexiform lesions in pulmonary-hypertension. J Pathol 1996; 179:A7
63. Stewart DJ, Levy RD, Cernacek P, et al. Increased plasma endothelin-1 in pulmonary-hypertension - marker or mediator of disease. Ann Intern Med 1991; 114:464-69
64. Giaid A, Yanagisaka M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary-hypertension. N Engl J Med 1993; 328:1732-39
65. Ferri C, Bellini C, De Angelis C, et al. Circulating endothelin-1 concentrations in patients with chronic hypoxia. J Clin Pathol 1995; 48:519-24
66. Goerre SM, Wenk M, Bartsch P, et al. Endothelin-1 in pulmonary hypertension associated with high-altitude exposure. Circulation 1995; 91:359-64
67. Kourembanas S, Marsden PA, Mcquillan LP, et al. Hypoxia induces endothelin gene-expression and secretion in cultured human endothelium. J Clin Invest 1991; 88:1054-57
68. Kavana AU, Lee M, Quertermous ME, et al. The loop interaction of GATA2 and AP1 regulates transcription of the endothelin-1 gene. Mol Cell Biol 1995; 15:4225-31
69. Kvietikova I, Wenger RH, Marti HH, et al. The transcription factors ATF-1 and CREB-1 bind constitutively to the hypoxic inducible factor-1 (HIF-1) DNA recognition site. Nucleic Acid Res 1995; 23:4542-50
70. Ziesche R, Petkov V, Williams J, et al. Lipopolysaccharide and interleukin-1 augment the effects of hypoxia and inflammation in human pulmonary arterial tissue. Proc Natl Acad Sci USA 1996; 93:12478-83
71. Luscher TF, Wenzel RR. Endothelin and endothelin antagonists: pharmacology and clinical implications. Agents Action Suppl 1995; 45:237-53
72. B receptors mediate contraction to endothelin-1 in human blood vessels. Circulation 1994; 89:1203-08
73. Herve P, Drouet L, Dosquet C, et al. Primary pulmonary hypertension in a patient with a familial platelet storage pool disease: role of serotonin. Am J Med 1990; 89:117-20
74. Herve P, Launay J-M, Scrobohaci M-L, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995; 99:249-54
75. Stelzner TJ, O'Brien RF, Yanagissawa M, et al. Increased lung endothelin-1 production in rats with idiopathic pulmonary hypertension. Am J Physiol 1992: 262:L614-20
76. Abenhaim L, Moride Y, Brenot F, et al, for the International Primary Pulmonary Hypertension Study Group. Appetite suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996; 335:609-16
77. Gonzalez AM, Smith APL, Emery CJ, et al. Platelet function in the Wistar and the fawn hooded rat: effect of chronic hypoxia [abstract]. Am J Respir Crit Care Med 1998; 157:A587